Lucky 13? Pace of 2006 CDER New Molecular Entity Approvals Bests 2005
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s drug review center appears to have a full slate of user fee goal dates in the coming months, holding the possibility of a continued rebound.